Please login to the form below

Not currently logged in
Email:
Password:

SurModics buys Brookwood Pharmaceuticals

SurModics acquires Brookwood Pharmaceuticals from Southern Research Institute for USD 40m to gain access to polymer microparticles technology

SurModics, a US-based surface modification and drug delivery technology company, has acquired Brookwood Pharmaceuticals from Southern Research Institute.

SurModics paid USD 40m in cash at closing and could pay up to an additional USD 22m in cash upon the successful achievement of certain revenue targets and development, regulatory and other milestones associated with customer projects.

Goldman, Sachs served as financial advisor to SurModics in this transaction, while Southern Research Institute was represented by Stonecroft Capital.

Brookwood is a US drug delivery company which specialises in polymer based enabling technologies and has particular strength in proprietary injectable microparticles and implant technology. Brookwood racked up USD 12.7m in revenue and strong year-over-year growth in 2006, mostly from R&D fees.

The company has nearly 30 development projects targeting a number of key clinical indications in the diabetes, oncology, ophthalmology, cardiovascular, orthopaedics, central nervous system and alcoholism markets.

1st August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...
Article: What's next? How behavioural science can support pharma's future
...
Video: UX/ Experience design research
...

Infographics